Published on | 4 months ago
Programmes Deployment: Best use of technologiesThe European Commission (DG CONNECT) has launched the following procurement procedure:
Better Internet for Kids (BIK) Platform – EU Coordination (EC-CNECT/LUX/2024/OP/0097)
The EU-funded Better Internet for Kids portal (at https://better-internet-for-kids.europa.eu) and the associated coordination tasks are the main subject of this call for tender. The BIK portal will cater to the needs of a community of Safer Internet Centres and support them in the delivery of online safety services aimed at children. This EU hub for child online safety is a key tool to support the European Commission in the implementation of the European strategy for a better internet for kids (‘Better Internet for Kids’, ‘BIK+ strategy’) (COM (2022)212) at national, European and international level.
Estimated value excluding VAT: €4,000,000
More information can be found on the Funding & Tenders Portal
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.